Medulloblastoma Recurrent Clinical Trials

6 recruitingLast updated: June 18, 2026

There are 6 actively recruiting medulloblastoma recurrent clinical trials across 8 countries. Studies span Phase 1, Phase 2, Early Phase 1, Not Applicable. Top locations include Washington D.C., District of Columbia, United States, St Louis, Missouri, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Medulloblastoma Recurrent Trials at a Glance

6 actively recruiting trials for medulloblastoma recurrent are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 1 with 2 trials, with the heaviest enrollment activity in Washington D.C., St Louis, and Houston. Lead sponsors running medulloblastoma recurrent studies include Children's National Research Institute, Fundación de investigación HM, and M.D. Anderson Cancer Center.

Browse medulloblastoma recurrent trials by phase

Treatments under study

About Medulloblastoma Recurrent Clinical Trials

Looking for clinical trials for Medulloblastoma Recurrent? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Medulloblastoma Recurrent trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Medulloblastoma Recurrent clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 1Phase 2

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

ParagangliomaPheochromocytomaSolid Tumor Cancer+19 more
Fundación de investigación HM25 enrolled1 locationNCT06607692
Recruiting
Phase 1

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

NeoplasmsNeoplasms by SiteBrain Diseases+30 more
M.D. Anderson Cancer Center24 enrolled3 locationsNCT03911388
Recruiting
Early Phase 1

A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.

PineoblastomaMedulloblastoma RecurrentHigh-Grade Gliomas+4 more
Children's National Research Institute18 enrolled1 locationNCT07017816
Recruiting
Not Applicable

Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma

MedulloblastomaEpendymomaEpendymoma of Brain+3 more
University of California, San Francisco74 enrolled8 locationsNCT05057702
Recruiting

Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study

Medulloblastoma RecurrentMedulloblastoma, Childhood, RecurrentMedulloblastoma, SHH-activated and TP53 Mutant+1 more
Mohammad H. Abu Arja300 enrolled2 locationsNCT07242963
Recruiting
Phase 2

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

Medulloblastoma RecurrentEpendymoma RecurrentATRT Recurrent+1 more
Medical University of Vienna232 enrolled22 locationsNCT01356290